GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U.S.

Shares of GSK plc GSK, Haleon plc HLN and other pharma companies, such as Sanofi SNY and Pfizer Inc. PFE fell on Thursday after the news of potential litigation around the heartburn drug Zantac ...

Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac. The lawsuits ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pfizer Inc. has agreed to settle more than 10,000 cases ...

The U.S. Food and Drug Administration announced Wednesday it is requesting manufacturers remove all prescription and over-the-counter ranitidine drugs from the market immediately. This is the latest ...

Pfizer (NYSE:PFE) has agreed to settle more than 10,000 lawsuits alleging that the company concealed cancer risks related to the discontinued heartburn drug Zantac, Bloomberg News reported Wednesday, ...

Following a string of legal wins this year—plus one major setback in May—GSK has washed its hands of yet another lawsuit alleging the once-popular heartburn med Zantac can cause cancer. GSK revealed ...

The verdict, in a case brought by plaintiff Angela Valadez, comes two years after a federal judge tossed all the plaintiffs' experts in the Zantac multidistrict litigation. Additional Zantac jury ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The ...